Treating to target in psoriatic arthritis

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 107-110

  Coates, Laura C ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

management; outcome measures; psoriatic arthritis; therapy; treat to target

Indexed keywords

DISEASE ACTIVITY; HUMAN; MANAGEMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN DISEASE; ARTHRITIS, PSORIATIC; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX;

EID: 84922415023     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000140     Document Type: Review

References (19)

1. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263-269.
2. Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 2014; 73:238-242.
3. Cherouvim EP, Zintzaras E, Boki KA, et al. Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: a 20- month open treatment. J Clin Rheumatol 2004; 10:162-168.
4. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-986.
5. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68:702-709.
6. Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25 (10):1957-1961.
7. Collantes-Estevez E, Munoz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in nonresponder patients with refractory spondyloarthropathies.Anopen extension of a multicentre study.Rheumatology (Oxford) 2005; 44:1555-1558.
8. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63:156-161.
9. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66:498-505.
10. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73:6-16.
11. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69:48-53.
12. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010; 62:970-976.
13. Coates LC, Helliwell PS. Validation of minimal disease activity for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010; 62:965-969.
14. Mease PJ, Heckaman M, Kary S, Kupper H. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013; 40:647-652.
15. Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013; 14:101.
16. Coates LC, Moverley AR, McParland L, et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 2013; 65:S346.
17. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013; 72:1358-1361.
18. Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2013-204858.
19. Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013; 72.